Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Contributed by: PR Newswire

Tags

Hansa-Biopharma-AB

More Like This

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial